Maternal hemodynamics in screen-positive and screen-negative women of the ASPRE trial.
Adult
Arterial Pressure
/ physiology
Birth Weight
/ physiology
Cardiac Output
/ physiology
Female
Fetal Distress
/ surgery
Fetal Growth Retardation
/ diagnosis
Hemodynamics
/ physiology
Humans
Hypertension, Pregnancy-Induced
/ physiopathology
Infant, Newborn
Longitudinal Studies
Perinatal Mortality
/ trends
Placenta Growth Factor
/ metabolism
Pre-Eclampsia
/ diagnosis
Pregnancy
Pregnancy Outcome
Pregnancy Trimester, First
/ metabolism
Pregnancy-Associated Plasma Protein-A
/ metabolism
Prospective Studies
Pulsatile Flow
/ physiology
Uterine Artery
/ diagnostic imaging
Vascular Resistance
/ physiology
bioreactance
cardiac output
fetal growth restriction
hemodynamic
peripheral vascular resistance
placental insufficiency
pre-eclampsia screening
Journal
Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
ISSN: 1469-0705
Titre abrégé: Ultrasound Obstet Gynecol
Pays: England
ID NLM: 9108340
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
13
06
2018
revised:
11
09
2018
accepted:
13
09
2018
pubmed:
25
9
2018
medline:
28
1
2020
entrez:
25
9
2018
Statut:
ppublish
Résumé
To compare maternal hemodynamics and perinatal outcome, in pregnancies that do not develop pre-eclampsia (PE) or deliver a small-for-gestational-age (SGA) neonate, between those identified at 11-13 weeks' gestation as being screen positive or negative for preterm PE, by a combination of maternal factors, mean arterial pressure, uterine artery pulsatility index, serum placental growth factor and pregnancy associated plasma protein-A. This was a prospective longitudinal cohort study of maternal cardiovascular function, assessed using a bioreactance method, in women undergoing first-trimester screening for PE. Maternal hemodynamics and perinatal outcome were compared between screen-positive and screen-negative women who did not have a medical comorbidity, did not develop PE or pregnancy-induced hypertension and delivered at term a live neonate with birth weight between the 5 The screen-negative group (n = 926) had normal cardiac function changes across gestation, whereas the screen-positive group (n = 170) demonstrated static or reduced cardiac output and stroke volume and higher mean arterial pressure and peripheral vascular resistance with advancing gestation. In the screen-positive group, compared with screen-negative women, birth-weight Z-score was shifted toward lower values, with prevalence of delivery of a neonate below the 35 Women who were screen positive for impaired placentation, even though they did not develop PE or deliver a SGA neonate, had pathological cardiac adaptation in pregnancy and increased risk of adverse perinatal outcome. Copyright © 2018 ISUOG. Published by John Wiley & Sons Ltd.
Substances chimiques
PGF protein, human
0
Placenta Growth Factor
144589-93-5
Pregnancy-Associated Plasma Protein-A
EC 3.4.24.-
Types de publication
Clinical Trial
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
51-57Subventions
Organisme : Fetal Medicine Foundation
ID : 1037116
Informations de copyright
Copyright © 2018 ISUOG. Published by John Wiley & Sons Ltd.